Investors have many different options when it comes to building exposure into the psychedelics sector within their portfolios. While some companies are undergoing large-scale and years-long clinical trials to prove efficacy, others are opening wellness clinics or cultivating mushrooms in legal jurisdictions.
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is a relatively new player to the psychedelics public markets space, but its management team has previous deep experience in another highly-regulated industry—cannabis—as former high-level executives at High Times. With its recent flurry of acquisitions, the team’s vision for the future of psychedelics is becoming increasingly clear and compelling to investors and the capital markets.
Let’s take a look at some of the recent acquisitions and why investors may want to take note.
Starting a Home Cultivation Movement
DELIC recently acquired a legacy counterculture distributor of psychedelic media and creator of one of the first self-contained mushroom grow kits. Before developing and selling tens of thousands of mushroom kits around the world, Homestead Book Company was one of the earliest distributors for High Times and other counterculture publications.
The acquisition enables DELIC to increase the products available on Reality Sandwich, which attracts over 200,000 unique visitors each month. In March, the company expects to launch a new mushroom kit that will have a modern interpretation of the company’s storied history and will include everything a consumer needs to become an at-home mycologist.
The company’s overarching goal is to become a leader in the home cultivation movement by leveraging a combination of educational content, innovative products and complementary products. With psychedelics limited to clinics at the moment, home cultivation could be a cornerstone of the mindfulness and meditative side of the movement.
Click here to receive an investor presentation and corporate updates
Building a Network of Ketamine Clinics
DELIC has also been targeting the “right-now” clinical side of the psychedelics industry with the acquisition of Ketamine Infusion Centers LLC last month. With two ketamine infusion treatment clinics in Arizona and California, the company offers ketamine as a mental health treatment for chronic mental health disorders including depression, anxiety, substance abuse, alcoholism, PTSD, and a range of other mental health disorders. Supported by clinical trials and peer reviewed studies, evidence of the efficacy of ketamine infusions is quickly growing.
By leveraging its existing media assets and connections, Delic hopes to supercharge the ketamine clinic business and scale up over time. DELIC’s access to the public markets could also support a more rapid expansion of the business, which has been growing quarter by quarter.
More recently, the company appointed Kyle Snook, former COO of Actify Neurotherapies, to its Board of Advisors. Actify Neurotherapies was a venture-backed startup that was formerly the largest provider of IV Ketamine Therapies nationwide. Combined with an MBA from Harvard Business School, Snook’s experience in the business will be instrumental to DELIC’s growth.
Amassing a Psilocybin IP Portfolio to Drive Value
DELIC is equally focused on building shareholder value through the acquisition of intellectual property in the psychedelics space with the acquisition of Complex Biotech Discovery Ventures (CBDV). In addition to being a profitable business with over 50 cannabis and psychedelics clients, CBDV’s licensed psilocybin and cannabis research lab is well-equipped for the development of IP.
The company aims to build out an IP portfolio of psilocybin analogs, novel compounds and deliver mechanisms that could pave the way for future medical treatments for depression, anxiety, PTSD and opioid substance abuse. With plans to apply for a dealer’s license, the company could also commercialize its research and IP portfolio over time.
The CBDV acquisition also adds strong scientific talent to DELIC’s overall management team. Dr. Markus Roggen brings a wealth of knowledge and industry experience that’s hard to find given the industry’s nascent stage. This leadership and expertise could help transform other businesses that DELIC acquires and better inform its long-term strategy in the space.
Click here to receive an investor presentation and corporate updates
Looking Ahead
Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) flurry of meaningful acquisitions over the past two months crystalizes its forward vision in the psychedelics space. With a broad focus on education, home cultivation, ketamine wellness clinics and IP psychedelic development, the company provides shareholders with diverse exposure to the industry and what could become a near-term path to profitability for investors.
For further information: Investor Relations Contact, Daniel Southern-Dwyer, Corporate Development, dsd@deliccorp.com
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
